Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Chipscreen Biosciences: Clinical Trials & FDA Approval Profile

Chipscreen Biosciences (Global / Institutional) sponsors 18 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (3 recruiting now), 10 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)5.6%
Median Closed Enrollment vs National (145 pts)47 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Chipscreen Biosciences
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)18
Active Pipeline (Recruiting Now)5 (3)
Completed vs Stopped Early10 / 1 (5.6%)
Median Closed Actual Enrollment47 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Chipscreen Biosciences
Hospital Research SiteLocationShared Protocols
Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality4
Sun Yat-sen University Cancer CenterGuangzhou, Guangdong4
Peking University People's HospitalBeijing, Beijing Municipality3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Chipscreen Biosciences
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT04807348Chiglitazar Added to Metformin for Type 2 DiabetesPhase IIICOMPLETED
NCT05193916A Phase II Clinical Trial of Chiglitazar for NASHPhase IICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the Chipscreen Biosciences Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI